多細胞三次元回転楕円体を生成するためのラボオンCDプラットフォーム

Executive Industry Relevance

The lab-on-a-CD platform enables rapid, reproducible generation of multicellular 3D spheroids under controlled centrifugal force, addressing a key bottleneck in preclinical model development. By supporting coculture of distinct cell types into defined architectures (concentric, Janus, sandwich), the system enhances mechanistic de-risking in target validation and phenotypic screening workflows. This capability improves predictive confidence in early discovery by providing disease-relevant, human-derived microtissues that better recapitulate in vivo cellular interactions than monolayer cultures.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses through controlled coculture of human adipose-derived stem cells and lung fibroblasts in defined spheroid geometries.
• Operational Value: Standardizes spheroid formation via precise centrifugal force application (1xg to 521xg), reducing variability in early-stage target engagement assays.

Screening & Assay Development

• Scientific Value: Produces uniform, spherically symmetric multicellular spheroids suitable for high-content imaging and quantitative readouts in drug screening.
• Operational Value: Features 100 identical 400 μm microwells per chip, enabling parallel assay execution and improved throughput for lead identification campaigns.

Translational & Preclinical Research

• Scientific Value: Supports generation of human-derived microtissues that maintain viability under prolonged high-gravity culture (up to 7 days), improving translational relevance of preclinical models.
• Operational Value: Compatible with standard cell culture incubators and fluorescence labeling protocols, facilitating integration into existing preclinical workflows without specialized equipment.

Pipeline & Workflow Integration

The CMS platform functions as a discovery-to-preclinical enabling technology, positioning spheroid generation between target validation and lead optimization stages by providing mechanistically informative, multicellular models.

• Discovery Biology: Supports hypothesis testing via controlled assembly of multicellular spheroids that clarify stromal-epithelial or stem cell-niche interactions in disease contexts.
• Screening: Delivers reproducible, quantifiable spheroid outputs with consistent size and morphology, enabling reliable compound response measurements across microwell arrays.
• Analytics: Generates fluorescence-compatible, structurally defined spheroids that support live/dead staining, imaging, and endpoint assays for comparative condition analysis.
• Translational Research: Uses human primary cells (adipose-derived stem cells, lung fibroblasts) to create disease-relevant systems that bridge discovery and preclinical validation.
• Enterprise Reuse: Fabricated from PDMS and polycarbonate via reusable CNC molds, the chip design supports standardization across teams and sites for scalable spheroid production.

Operational & Enterprise Impact

• Scientific Value: Enhances predictive confidence by reducing mechanistic ambiguity in coculture models through precise spatial control of cell populations.
• Operational Value: Ensures standardization and reproducibility via centrifugal force-driven uniform cell deposition into microwells, minimizing well-to-well variability.
• Strategic Value: Improves go/no-go decisions by enabling early assessment of compound effects in complex, human-relevant microtissues, reducing late-stage attrition risk.
• Portfolio Impact: Supports risk-adjusted prioritization through generation of structured coculture spheroids that inform target selection and lead optimization.

Implementation Considerations

• Requires expertise in microfluidic chip handling, centrifugal force calibration, and sterile cell culture techniques.
• Dependent on access to a programmable motor-driven rotation system capable of 500–5,200 RPM and CNC-fabricated polycarbonate molds for PDMS chip replication.
• Necessitates cross-team standardization of rotation protocols, cell seeding densities, and medium exchange schedules to ensure spheroid uniformity.
• Adaptation to alternative cell types may require optimization of Pluronic F-127 coating duration and rotation speeds to prevent aggregation or uneven microwell occupancy.
• Practical limitations include manual alignment of top/bottom chip layers during bonding, which affects microwell cell count consistency if misaligned.

Biopharma FAQs